These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33532318)

  • 1. Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review.
    Liu YX; Le KJ; Shi HY; Zhang ZL; Cui M; Zhong H; Yu YT; Gu ZC
    Transl Androl Urol; 2021 Jan; 10(1):292-299. PubMed ID: 33532318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports.
    Charles R; Adhikari SD; Mittal A; Chaudhuri S; Gupta M; Khot W; Schito M; Gupta N
    Infez Med; 2022; 30(4):516-524. PubMed ID: 36482959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials.
    Chen M; Zhang M; Huang P; Lin Q; Sun C; Zeng H; Deng Y
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):111-120. PubMed ID: 29343141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful High-Dosage Monotherapy of Tigecycline in a Multidrug-Resistant
    Van der Weide H; Ten Kate MT; Vermeulen-de Jongh DMC; Van der Meijden A; Wijma RA; Boers SA; Van Westreenen M; Hays JP; Goessens WHF; Bakker-Woudenberg IAJM
    Antibiotics (Basel); 2020 Mar; 9(3):. PubMed ID: 32138210
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of initial antibiotic treatment failure: Real-world insights in patients with complicated urinary tract infection.
    Karve S; Ryan K; Peeters P; Baelen E; Rojas-Farreras S; Potter D; Rodríguez-Baño J
    J Infect; 2018 Feb; 76(2):121-131. PubMed ID: 29128389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Donor-derived Carbapenem-resistant Klebsiella pneumoniae Infection after Renal Transplantation with Tigecycline and Extended-infusion Meropenem.
    Wang ZQ; Guo ZL; Feng H; Fu C; Zhao GY; Ma K; Zhu L; Chen G
    Curr Med Sci; 2021 Aug; 41(4):770-776. PubMed ID: 34403102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study.
    Mouloudi E; Massa E; Piperidou M; Papadopoulos S; Iosifidis E; Roilides I; Theodoridou T; Kydona C; Fouzas I; Imvrios G; Papanikolaou V; Gritsi-Gerogianni N
    Transplant Proc; 2014 Nov; 46(9):3219-21. PubMed ID: 25420864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and risk factors of catheter-associated urinary tract infections caused by Klebsiella Pneumoniae.
    Liu X; Sai F; Li L; Zhu C; Huang H
    Ann Palliat Med; 2020 Sep; 9(5):2668-2677. PubMed ID: 32921093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW; Long J; Huntington JA
    BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections.
    Gomila A; Shaw E; Carratalà J; Leibovici L; Tebé C; Wiegand I; Vallejo-Torres L; Vigo JM; Morris S; Stoddart M; Grier S; Vank C; Cuperus N; Van den Heuvel L; Eliakim-Raz N; Vuong C; MacGowan A; Addy I; Pujol M;
    Antimicrob Resist Infect Control; 2018; 7():111. PubMed ID: 30220999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of Tigecycline Nonsusceptible and IMP-4 Carbapenemase-Producing K2-ST65 Hypervirulent Klebsiella pneumoniae in China.
    Zhang Y; Wang X; Wang Q; Chen H; Li H; Wang S; Wang R; Wang H
    Microbiol Spectr; 2021 Oct; 9(2):e0130521. PubMed ID: 34704778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of Mobile Tigecycline Resistance Gene
    Zhai W; Tian Y; Lu M; Zhang M; Song H; Fu Y; Ma T; Sun C; Bai L; Wang Y; Liu D; Zhang Y
    Microbiol Spectr; 2022 Feb; 10(1):e0108121. PubMed ID: 35138117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
    J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.
    Zha L; Pan L; Guo J; French N; Villanueva EV; Tefsen B
    Adv Ther; 2020 Mar; 37(3):1049-1064. PubMed ID: 32006240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis.
    Ezure Y; Rico V; Paterson DL; Hall L; Harris PNA; Soriano A; Roberts JA; Bassetti M; Roberts MJ; Righi E; Wright H
    Open Forum Infect Dis; 2022 May; 9(5):ofaa480. PubMed ID: 35474756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline resistance among carbapenem-resistant Klebsiella Pneumoniae: Clinical characteristics and expression levels of efflux pump genes.
    Chiu SK; Chan MC; Huang LY; Lin YT; Lin JC; Lu PL; Siu LK; Chang FY; Yeh KM
    PLoS One; 2017; 12(4):e0175140. PubMed ID: 28388651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence and characterization of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae isolates from blood samples of patients in intensive care units in northern China.
    Xu H; Zhou Y; Zhai X; Du Z; Wu H; Han Y; Huo C; Chen Y
    J Med Microbiol; 2016 Aug; 65(8):751-759. PubMed ID: 27324378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.